Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Aspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice

View through Europeana Collections
Metformin is the first line therapy of type 2 diabetics, but continued reduction of their life expectancy warrants further investigation into alternative treatment strategies. This study reports on the combinational use of metformin with aspalathin, a C-glucosyl dihydrochalcone with known glucose lowering and antioxidant properties, as an effective hypoglycemic therapy in a type 2 diabetic (db/db) mouse model. When tested as a monotherapy, a low dose of aspalathin (13 mg/kg) showed no effect, while a high dose (130 mg/kg) has already displayed a better potential than metformin in protecting against diabetes associated symptoms in db/db mice. Thus, it remains of interest to determine whether this dihydrochalcone can improve the efficacy of metformin. The results showed that this combination therapy was more effective than the use of metformin as a monotherapy in ameliorating diabetes associated symptoms, including abnormal raised fasting plasma glucose levels, impaired glucose tolerance, as well as excessively increased body weights and fat content. The treated mice also had reduced food and water consumption when compared to untreated controls, with a pronounced effect evident in the last week of treatment. Therefore, this study supports further investigations into the ameliorative effect of combination therapy of metformin and aspalathin against diabetes associated symptoms.
Library of the Czech Academy of Sciences
Title: Aspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice
Description:
Metformin is the first line therapy of type 2 diabetics, but continued reduction of their life expectancy warrants further investigation into alternative treatment strategies.
This study reports on the combinational use of metformin with aspalathin, a C-glucosyl dihydrochalcone with known glucose lowering and antioxidant properties, as an effective hypoglycemic therapy in a type 2 diabetic (db/db) mouse model.
When tested as a monotherapy, a low dose of aspalathin (13 mg/kg) showed no effect, while a high dose (130 mg/kg) has already displayed a better potential than metformin in protecting against diabetes associated symptoms in db/db mice.
Thus, it remains of interest to determine whether this dihydrochalcone can improve the efficacy of metformin.
The results showed that this combination therapy was more effective than the use of metformin as a monotherapy in ameliorating diabetes associated symptoms, including abnormal raised fasting plasma glucose levels, impaired glucose tolerance, as well as excessively increased body weights and fat content.
The treated mice also had reduced food and water consumption when compared to untreated controls, with a pronounced effect evident in the last week of treatment.
Therefore, this study supports further investigations into the ameliorative effect of combination therapy of metformin and aspalathin against diabetes associated symptoms.

Related Results

OR-010 The potential role of MG53 in exercise-mediated modulation of diabetic cardiomyopathy in db/db mice
OR-010 The potential role of MG53 in exercise-mediated modulation of diabetic cardiomyopathy in db/db mice
Objective Diabetic cardiomyopathy is a major complication of Type 2 diabetes. Recent studies have shown that as an E3 ligase targeting insulin receptor (IR) and insulin receptor su...
Evidence against Pathway-Selective Hepatic Insulin Resistance in Mice
Evidence against Pathway-Selective Hepatic Insulin Resistance in Mice
Insulin suppresses hepatic glucose production and increases hepatic de novo lipogenesis (DNL). Paradoxically, hepatic DNL remains elevated in insulin-resistant subjects, leading to...
PO-063 Exercise alleviates insulin resistance by regulating MG53 and IR/IRS/AKT/mTOR signaling in db/db mice skeletal muscle
PO-063 Exercise alleviates insulin resistance by regulating MG53 and IR/IRS/AKT/mTOR signaling in db/db mice skeletal muscle
Objective In the current study, we aim to investigate whether 12-week treadmill exercise alleviates insulin resistance and muscle atrophy, and to explore whether MG53 along with IR...
Abstract 2172: Dying tumor cells (tumor debris) stimulate the growth of 4T1 breast cancer tumor in female athymic nude mice
Abstract 2172: Dying tumor cells (tumor debris) stimulate the growth of 4T1 breast cancer tumor in female athymic nude mice
Abstract Current cancer therapies are based on chemotherapy and radiation. These therapeutic approaches can initially reduce the tumor mass or tumor burden by killin...
MAMMARY GROWTH AND FUNCTION AND PITUITARY PROLACTIN SECRETION IN FEMALE NUDE MICE
MAMMARY GROWTH AND FUNCTION AND PITUITARY PROLACTIN SECRETION IN FEMALE NUDE MICE
ABSTRACT Mammary structural growth in the wholemount preparation, content and synthesis of mammary DNA and RNA estimated by the incorporation of [3H]thymidine and [14C]uridine, pit...
The Various Methods on Early Stage Detection of Diabetic Retinopathy
The Various Methods on Early Stage Detection of Diabetic Retinopathy
The leading cause for the blindness in the diabetic patients is due to the Diabetic Retinopathy. According to the recent statistics from the US centre for Disease and prevention es...
The effect of endometriosis on fertility in an animal model
The effect of endometriosis on fertility in an animal model
The present experimental model aimed to investigate the possible effect of endometriosis on ovarian function by altering follicular maturation and development. This single-blind, r...
Cardiac Autonomic Neuropathy in Type 1 Diabetes Mellitus: A Case Report
Cardiac Autonomic Neuropathy in Type 1 Diabetes Mellitus: A Case Report
Cardiac Autonomic Neuropathy (CAN) is a well-recognized complication of diabetes mellitus that affects both type 1 and type 2 diabetic patients. Its clinical presentation can be s...

Back to Top